← All indications
Mycosis Fungoides
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
Subtype terms (1)
More specific conditions that are subtypes of Mycosis Fungoides in the MeSH hierarchy.
Drugs by status
Approved for this indication (8)
Phase 4 trials (8)
Phase 3 trials (10)
Phase 2 trials (28)
- resimmune
- afm13
- aminolevulinic acid
- lenalidomide
- doxycycline
- durvalumab
- gemcitabine
- nivolumab
- pembrolizumab
- ritlecitinib
- pralatrexate
- interleukin-12
- resminostat
- sitagliptin
- cyclophosphamide
- talimogene laherparepvec
- dasatinib
- alemtuzumab
- vorinostat
- fludarabine
- triamcinolone
- romidepsin
- agatolimod
- isotretinoin
- cemiplimab
- tavokinogene telseplasmid
- magrolimab
- mt-101
Phase 1 trials (33)
- avelumab
- belinostat
- bendamustine
- carfilzomib
- folic acid
- obinutuzumab
- genetically engineered lymphocyte therapy
- cyanocobalamin
- imiquimod
- medi-570
- mrg-106
- silver nanoparticles
- trastuzumab
- ifosfamide
- ipilimumab
- carboplatin
- interleukin-15
- tti-621
- cd30-car t cells
- genetically modified t cells # 1138
- mesna
- vsv-hifnbeta-nis
- rituximab
- daratumumab
- etoposide
- fludeoxyglucose f-18
- parsaclisib
- fenretinide
- cpi-0209
- wu-cart-007
- +3 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (14)
- Ligand Pharmaceuticals
- Eisai
- Mallinckrodt
- University of Pittsburgh
- Boston University
- Case Western Reserve University
- Madrilenian Group of Cutaneous Lymphomas
- Polish Lymphoma Research Group
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- Vanderbilt University
- University of Minnesota
- Rush University
- University of Texas at Houston
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (59)
- 4SC AG
- Actelion
- Ceptaris
- Celgene
- Roche
- Genzyme
- Angimmune LLC
- Innate Pharma
- OncoSec Medical Incorporated
- miRagen Therapeutics, Inc.
- Affimed GmbH
- Neumedicines Inc.
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- American Society of Clinical Oncology
- Cancer and Leukemia Group B (CALGB)
- Cornell University
- Harvard University
- Emory University
- Temple University
- University of Washington
- Hoosier Cancer Research Network
- James Graham Brown Cancer Center
- Latin American Cooperative Onco-Haematology Group - Peru
- Northwestern University
- Ohio State University
- Rutgers University
- Stanford University
- +29 more
Organization Involved with Phase 1 Indications (17)
- Spectrum Pharmaceuticals
- Amgen
- Morphotek
- Arno Therapeutics
- Sorrento Therapeutics, Inc.
- Trillium Therapeutics Inc.
- AIDS Malignancy Consortium
- Johns Hopkins University
- Southwest Oncology Group
- University of Toronto
- Virginia Commonwealth University
- Wake Forest University
- University of Cologne
- University of North Carolina at Chapel Hill
- University of Wisconsin
- SciTech Development, LLC
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (1)